avasimibe has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bailey, D; Brown, R; Davidson, AD; Erdmann, M; Hansen, SB; Hinks, TS; Maini, MK; McKeating, JA; Morgan, SB; Newman, J; Peters, R; Schmidt, NM; Shionoya, K; Swadling, L; Thakur, N; Wang, H; Watashi, K; Wing, PAC | 1 |
1 other study(ies) available for avasimibe and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity.
Topics: Acyltransferases; Antiviral Agents; COVID-19; Humans; SARS-CoV-2; T-Lymphocytes | 2023 |